細胞程序性死亡蛋白1(PD1)多克隆抗體
Polyclonal Antibody to Programmed Cell Death Protein 1 (PD1)
CD279; PDCD1; SLEB2; HPD1P
- 編號UPAA751Hu01
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 來源多抗制備
- 宿主兔
- 效價-
- Ig類型 IgG
- 純化方式抗原特異性親和純化
- 標記物無標記物
- 免疫原 RPA751Hu01-細胞程序性死亡蛋白1(PD1)重組蛋白
- 緩沖液成份0.01M 磷酸鹽緩沖液（pH7.4，containing 0.05% Proclin-300，50% glycerol）
- 性狀液體
- 濃度0.5mg/mL
- 且適物種Rattus norvegicus (Rat，大鼠), Sus scrofa; Porcine (Pig，豬)
- 應用WB; IHC; ICC/IF
如果抗體需用于流式細胞術，請參見流式抗體。 - 下載 英文說明書 中文說明書
- 規(guī)格 20μl100μl 200μl 1ml 10ml
- 價格 ¥ 284 ¥ 664 ¥ 948 ¥ 2370 ¥ 9480
- 欲了解實際交易價格和更多情況，請與當?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
DAB staining on IHC-P; Sample: Human Breast cancer Tissue; Primary Ab: 20ug/ml Rabbit Anti-Human PDCD1 Antibody Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody (Catalog: SAA544Rb19)
-
DAB staining on IHC-P;
Sample: Human Lung Tissue;
Primary Ab: 20ug/ml Rabbit Anti-Human PDCD1 Antibody
Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
(Catalog: SAA544Rb19) -
DAB staining on IHC-P;
Sample: Human Breast cancer Tissue
Primary Ab: 20μg/ml Rabbit Anti-Human PDCD1 Antibody
Control: Used PBS instead of primary antibody
Second Ab: 2μg/ml HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
(Catalog: SAA544Rb19) -
DAB staining on IHC-P;
Sample: Human Ovarian cancer Tissue;
Primary Ab: 10μg/ml Rabbit Anti-Human PDCD1 Antibody
Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
(Catalog: SAA544Rb19)
Secondary antibody only control: Used PBS instead of primary antibody, Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
(Catalog: SAA544Rb19) -
DAB staining on IHC-P;
Sample: Human Tonsil Tissue;
Primary Ab: 10μg/ml Rabbit Anti-Human PDCD1 Antibody
Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
(Catalog: SAA544Rb19)
Secondary antibody only control: Used PBS instead of primary antibody, Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
(Catalog: SAA544Rb19) -
DAB staining on IHC-P;
Sample: Human Appendix Tissue;
Primary Ab: 20ug/ml Rabbit Anti-Human PDCD1 Antibody
Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
(Catalog: SAA544Rb19) -
DAB staining on IHC-P;
Sample: Human Kidney Tissue;
Primary Ab: 20ug/ml Rabbit Anti-Human PDCD1 Antibody
Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
(Catalog: SAA544Rb19) -
DAB staining on IHC-P;
Sample: Human Lung Tissue
Primary Ab: 20μg/ml Rabbit Anti-Human PDCD1 Antibody
Control: Used PBS instead of primary antibody
Second Ab: 2μg/ml HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
(Catalog: SAA544Rb19) -
FITC staining on IF;
Sample: 293F cell
Primary Ab: 20μg/ml Rabbit Anti-Human PDCD1 Antibody
Second Ab: 2μg/ml FITC-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
(Catalog: SAA544Rb11)
-
Western Blot; Sample: Rat Spleen lysate Primary Ab: 0.1μg/ml Rabbit Anti-Human PDCD1 Antibody Second Ab: 0.2μg/mL HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody (Catalog: SAA544Rb19) Selected
-
Western Blot; Sample: Porcine Lymph node lysate; <br/>Primary Ab: 5μg/ml Rabbit Anti-Human PDCD1 Antibody<br/>Second Ab: 0.2μg/mL?HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody<br/>(Catalog: SAA544Rb19) Selected
-
通過ISO 9001、ISO 13485質(zhì)量體系認證
特異性
該抗體是針對PD1的兔多克隆抗體。在免疫組織化學染色和免疫印跡實驗中能識別PD1。
用法
Western blotting: 0.01-5μg/mL;
Immunohistochemistry: 5-20μg/mL;
Immunofluorescence: 5-20μg/mL;
Optimal working dilutions must be determined by end user.
儲存
經(jīng)常使用則4°C保存。-20°C保存不超過兩年。避免反復凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定，具體方法如下：在37°C孵育48小時，沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當?shù)臈l件下存儲，損失率低于5%。
贈品
增值服務
相關產(chǎn)品
| 編號 | 適用物種：Homo sapiens (Human，人) | 應用(僅供研究使用，不用于臨床診斷！) |
| UAPA751Hu02 | 細胞程序性死亡蛋白1(PD1)活性蛋白 | Cell?culture;?Activity?Assays. |
| UAPA751Hu01 | 細胞程序性死亡蛋白1(PD1)活性蛋白 | Cell?culture;?Activity?Assays. |
| URPA751Hu01 | 細胞程序性死亡蛋白1(PD1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UEPA751Hu61 | 細胞程序性死亡蛋白1(PD1)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UAPA751Hu61 | 細胞程序性死亡蛋白1(PD1)活性蛋白 | Cell?culture;?Activity?Assays. |
| URPA751Hu02 | 細胞程序性死亡蛋白1(PD1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAA751Hu02 | 細胞程序性死亡蛋白1(PD1)多克隆抗體 | WB; IHC; ICC; IP. |
| UPAA751Hu01 | 細胞程序性死亡蛋白1(PD1)多克隆抗體 | WB; IHC; ICC/IF |
| URAA751Hu23 | 細胞程序性死亡蛋白1(PD1)重組抗體 | FCM |
| UMAA751Hu24 | 細胞程序性死亡蛋白1(PD1)單克隆抗體 | WB |
| UMAA751Hu25 | 細胞程序性死亡蛋白1(PD1)單克隆抗體 | WB; IHC; ICC; IP. |
| URAA751Hu01 | 細胞程序性死亡蛋白1(PD1)重組抗體 | ICC/IF |
| UMAA751Hu27 | 細胞程序性死亡蛋白1(PD1)單克隆抗體 | WB; IHC; ICC; IP. |
| UMAA751Hu21 | 細胞程序性死亡蛋白1(PD1)單克隆抗體 | WB |
| UMAA751Hu29 | 細胞程序性死亡蛋白1(PD1)單克隆抗體 | WB; IHC; ICC; IP. |
| URAA751Hu22 | 細胞程序性死亡蛋白1(PD1)重組抗體 | WB; IF; ICC; IHC; IP; FCM. |
| UMAA751Hu23 | 細胞程序性死亡蛋白1(PD1)單克隆抗體 | WB |
| UMAA751Hu22 | 細胞程序性死亡蛋白1(PD1)單克隆抗體 | WB; IHC; ICC; IP. |
| UFAA751Hu86 | 抗細胞程序性死亡蛋白1(PD1)單克隆抗體(異硫氰酸熒光素標記) | Flow cytometry. |
| USEA751Hu | 細胞程序性死亡蛋白1(PD1)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| ULMA751Hu | 細胞程序性死亡蛋白1(PD1)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| UKSA751Hu01 | 細胞程序性死亡蛋白1(PD1)檢測試劑盒DIY材料(酶聯(lián)免疫吸附試驗法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻
| 雜志 | 參考文獻 |
| Oncotarget | Circulating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infection. [pubmed:28545019] |
| CyberLeninka | Потенциальные биомаркеры эффективности терапии ниволумабом при метастатическом почечно-клеточном раке [:] |
| АНАЛИЗ РЕЗУЛЬТАТОВ ЛЕЧЕНИЯ БОЛЬНЫХ МЕТАСТАТИЧЕСКИМ РАКОМ ПОЧКИ, ПОЛУЧАВШИХ АНТИ-PD-1?ТЕРАПИЮ В РАМКАХ ПРОГРАММЫ?… [] | |
| International Journal of Molecular?Sciences | Design and Synthesis of A PD-1 Binding Peptide and Evaluation of Its Anti-Tumor Activity [Pubmed: 30699956] |
| PLoS?One | Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated?… [Pubmed: 30807610] |
| Cancers | Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study [Pubmed: 32085544] |
留言咨詢
